Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1601mAb, an investigational treatment designed to target BSP1 for various cancers; MS-1601A, which addresses both cancerous and autoimmune diseases by targeting TRG1; and vactosertib, a therapeutic candidate aimed at solid tumors. MedPacto is headquartered in Seoul, South Korea.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.